-
Charlie Puth and Ellie Goulding to Headline First Johnnie & Co. Festival in Mumbai
-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
Alset AI Closes Non-Brokered Private Placement Offering
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
Who Does the Best Rhinoplasty in Sarasota?
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
Dateline appoints Tony Ferguson as Acting Chairman
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
Ondas, Palantir and Regna AI Host Key Defense Technology Leaders to Accelerate the Path from AI Innovation to Fielded Capability
-
Taylor Bank Announces $125,000 Commitment to Diakonia's Supportive Living Campus Capital Campaign
-
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
-
First Phosphate and Zeo Energy Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Kartoon Studios' Beacon Media Partners With Bandai on Tamagotchi's Landmark 30th Anniversary Times Square Celebration
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, is pleased to announce the launch of an important large-mass animal bioequivalence study for its lead product, BNT23001, a proprietary sublingual Cladribine formulation for the treatment of multiple sclerosis ("MS"). This is the final animal study to generate dosing parameters for the Company's human comparative bioequivalence study planned for early 2026.
"The Company has already confirmed dosage bioequivalence in small-mass (40kgs) animal study will provide valuable insight into the appropriate sublingual drug load for humans," Hugh Rogers, CEO of BioNxt. "This large-mass animal study is expected to increase the formula precision in our human study and is designed to generate comparative drug absorption results between the Company's sublingual formulation versus the name brand tablet formulation. Optimization of drug load per dose and potential super bioavailability are key pieces of information that will guide the final clinical planning for our upcoming comparative human bioequivalence study."
The large-mass animal crossover bioequivalence study will commence in the next two to three weeks and will be carried out over the following 15 days. The study is expected to be completed in November with results available in December.
BNT23001 is an orally dissolvable thin-film formulation of cladribine, a well-established immunomodulatory compound used for the treatment of MS. Delivered sublingually, the formulation is designed for improved bioavailability, faster onset of action, and enhanced patient compliance, particularly in populations affected by dysphagia or seeking non-invasive alternatives to traditional tablets or injections. Preclinical studies, as previously reported, have demonstrated high absorption rates and bioequivalence to existing oral therapies as well as zero indications of toxicity.
The patent nationalization process is underway in key global markets, including the European Union, Canada, Australia, Eurasia, New Zealand, and Japan, as well a Track One priority filing in the United States. Both the European Patent Office and the Eurasian Patent Office have issued favorable communications, including notice of intentions to grant. Novelty, inventive step, and industrial applicability were fully accepted.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumors while reducing side effects.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: [email protected]
Phone: +1 604.250.6162
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Such information may include, but is not limited to, statements regarding: the anticipated grant, scope, and timing of European, Eurasian, and other international patent rights; the Company's plans for additional national filings; the development, clinical evaluation, regulatory approval, and commercialization of the Company's Cladribine sublingual thin-film (BNT23001) for multiple sclerosis; the strategic importance of intellectual property protection; the timing, cost, and outcome of preclinical and clinical studies; and the potential application of BioNxt's sublingual thin-film drug delivery platform across additional therapeutic areas.
Forward-looking information is based on management's current expectations, assumptions, estimates, and projections as of the date of this press release. Such statements are subject to inherent risks and uncertainties, many of which are beyond the Company's control, that could cause actual results, performance, or achievements to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to: outcomes of patent examination and prosecution processes; changes in regulatory requirements or legal frameworks; the results, timing, and costs of preclinical and clinical studies; scalability and reproducibility of manufacturing processes; the availability of strategic partnerships and funding; and broader economic, financial, or geopolitical factors.
Readers are cautioned not to place undue reliance on forward-looking information. Although the Company believes the expectations and assumptions underlying such information are reasonable, there can be no assurance that they will prove to be correct. Except as required under applicable securities laws, BioNxt undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
F.Ramirez--AT